Extended Data Fig. 8: In vitro and in vivo evaluation of the anticancer efficiency of ABCs with different payloads on BT-474 cells or xenograft tumor model.
From: Antibody–bottlebrush prodrug conjugates for targeted cancer therapy
a. Cell viability studies for ABCs with different payloads compared to their nontargeting BPs (top and middle row, from left to right: MMAE, SN-38, and DOX; top row: 2 days incubation; bottom row: 5 days incubation) and different ADCs (bottom row, from left to right: T-DM1 and T-DXd, 2 d or 5 d incubation). Each data point represents the mean of three independent replicates (n = 3 biological replicates). b. BT-474 tumor volumes at day 40 for mice given MMAE-based ABCs and non-targeted controls (n = 4 mice/group). c. Ex vivo images of the tumors at day 40 for mice given MMAE-based constructs. d. Enlarged Fig. 3d for tumor volume measurement with dose schedule illustrated via green arrows (n = 6 mice/group). e. SDS-PAGE analysis of ABCs with DOX as the payload. f. BT-474 tumor volumes at day 40 for mice given DOX-based ABCs and non-targeted controls (n = 6 mice/group). g. Ex vivo images of the tumors at day 40 for mice given DOX-based constructs. Results are presented as mean ± SEM. Statistical analysis was done using a 2-tailed t-test. For these statistical tests, NS denotes non-significant; *, P < 0.05; **, P < 0.01.
